JMP Securities analyst Jason Butler raised the firm’s price target on Argenx (ARGX) to $696 from $606 and keeps an Outperform rating on the shares. Argenx continues to impress on all fronts, with further VYVGART outperformance and development execution, with continued growth in generalized myasthenia gravis and launch success in chronic inflammatory demyelinating polyneuropathy, the analyst tells investors in a research note. Even with robust commercial and pipeline investment, Argenx expects to be profitable in 2025, the firm says.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx SE Outlines 2025 Strategic Priorities Amid Strong Sales
- Argenx reports preliminary Q4 revenue $737M, consensus $627.99M
- Argenx sees FY24 revenue $2.2B, consensus $2.01B
- Argenx price target raised to $761 from $717 at BofA
- Halozyme announces Vyvdura co-formulated with Enhanze granted MHLW approval